Mosquitoes that landed on surfaces coated with the antimalarial compound atovaquone were completely blocked from developing Plasmodium falciparum (P. falciparum), the parasite that causes malaria, according to new research led by Harvard T.H. Chan School of Public Health.
The study showed that atovaquone—an active ingredient in medication that’s commonly used in humans to prevent and treat malaria—can be absorbed through mosquitoes’ tarsi (legs) and prevents the insects from developing and spreading the parasite. The findings indicate that treating bed nets with atovaquone or similar compounds would be an effective way to reduce the burden of malaria while significantly mitigating the growing problem of insecticide resistance.
“Mosquitoes are amazingly resilient organisms that have developed resistance against every insecticide that has been used to kill them. By eliminating malaria parasites within the mosquito rather than killing the mosquito itself, we can circumvent this resistance and effectively prevent malaria transmission,” said Flaminia Catteruccia, professor of immunology and infectious diseases. “Ultimately, the use of antimalarials on mosquito nets could help eliminate this devastating disease. It’s a simple but innovative idea that’s safe for people who use mosquito nets and friendly to the environment.”
The study was published online in Nature on February 27, 2019.
Malaria poses a risk to nearly half of the world’s population. Annually, more than 200 million people become sick with malaria and more than 400,000 people die from it. During the past 20 years, bed nets treated with long-lasting insecticides that kill mosquitoes have significantly reduced the global malaria burden. It’s estimated that such bed nets are responsible for 68% of all malaria cases averted since 2000. Recent years, however, have seen a surge in mosquitoes that are resistant to the most commonly used insecticides. In some malaria hot spots, there is near total resistance to pyrethroids, one of the key groups of insecticides currently in use. The waning effectiveness of insecticides is a public health emergency that threatens to undo decades of progress toward controlling malaria and highlights the urgent need to develop new approaches to stop the spread of the disease.
For this study, the researchers reasoned that they could introduce antimalarial compounds to Anopheles mosquitoes in a way that’s similar to a mosquito making contact with insecticides on a bed net. Rather than kill the mosquitoes, the aim was to give them a prophylactic treatment so that they could not develop and transmit the malaria-causing parasite.
To test the approach, they coated glass surfaces with atovaquone and covered them with a plastic cup. Female mosquitoes were then introduced into the cup. Prior to or immediately after the mosquitoes made contact with the atovaquone-coated glass, the researchers infected them with P. falciparum. Over the course of the study, mosquitoes were exposed to different concentrations of atovaquone and were kept in the cups for different amount of times.
The study found that P. falciparum development was completely blocked at relatively low concentrations of atovaquone (100 ?mol per m2) and when mosquitoes were exposed for just 6 minutes, which is comparable to the time wild mosquitoes spend on insecticide-treated bed nets. The researchers had similar success when using other compounds similar to atovaquone. While atovaquone effectively killed parasites, it had no effects on mosquito lifespan or reproduction.
“When we put these data into a mathematical model using real-world data on insecticide resistance, bed net coverage and malaria prevalence, it showed that supplementing conventional bed nets with a compound like atovaquone could appreciably reduce malaria transmission under almost any conditions we had data for in Africa,” said Douglas Paton, research fellow and lead author of the paper. “What got us really excited is that it also showed that this new intervention would have the greatest impact in areas with the highest levels of mosquito insecticide resistance.”
The Latest on: Atovaquone
via Google News
The Latest on: Atovaquone
- A Man With Fever, Fatigue, and a Trip to Nigeriaon March 4, 2021 at 9:10 am
A 36-year-old man returns from a trip to Nigeria with fever, fatigue, and muscle aches. Blood cultures drawn at urgent care and a rapid diagnostic test for malaria are negative. What's your diagnosis?
- Anti-Malarial Drugs Market Growth, Industry Analysis | Global And Regional Market Forecast To 2020 -2025|KDMIon February 26, 2021 at 12:01 am
atovaquone, primaquine, halofantrine, doxycycline, and clindamycin. The market for quinine is anticipated to witness significant growth during the forecast period. Further, global anti-malarial drugs ...
- Atovaquone and Proguanilon February 25, 2021 at 4:00 pm
This information from Lexicomp ® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. If you ...
- Anti-malarial Medicines Market 2021 : Latest Industry Trends, Growth, Share, Size and 2026 Forecast Research Report with Top countries Dataon February 24, 2021 at 6:48 pm
Feb 25, 2021 (The Expresswire) -- According to 360 Research Reports, the “Anti-malarial Medicines Market" 2021 by Types (Atovaquone Plus Proguanil, Doxycycline, Mefloquine, Chloroquine and Proguanil, ...
- Atovaquone-Proguanil HCLon February 22, 2021 at 12:50 pm
Dosage in children is also based on weight. To prevent illness, take atovaquone/proguanil usually once daily at the same time each day, or as directed by your doctor. Start this medication 1-2 ...
- Plasmodium falciparum Malaria and Atovaquone-Proguanil Treatment Failureon February 15, 2021 at 3:59 pm
The patient was hospitalized and immediately treated with the standard dosage of A-P (Malarone, 4 tablets each day for 3 days given with the main meal; each tablet contains 250 mg of atovaquone ...
- Researchers survey repurposed drugs that inhibit SARS-CoV-2 replication in vitroon February 3, 2021 at 5:35 am
Antihypertensives such as manidipine, and antimicrobials like atovaquone and amodiaquine also showed equivalent inhibition. So did some drugs already being studied for the treatment of this infection.
- Atovaquone/Rifabutin Interactionson January 21, 2021 at 11:40 am
1.Mepron (atovaquone) US prescribing information. GlaxoSmithKline July, 2019. 2.Malarone (atovaquone and proguanil hydrochloride) US prescribing information. GlaxoSmithKline March, 2010.
- Anti-Malarial Drugs Market Size, Key Players, Segmentation, Demand, Growth, Trend, Opportunity and Forecast to 2027on January 18, 2021 at 4:00 pm
The MarketWatch News Department was not involved in the creation of this content. Jan 19, 2021 (AmericaNewsHour) -- The report titled "Anti-Malarial Drugs Market: Global Demand Analysis ...
- Atovaquone and Azithromycin for the Treatment of Cytauxzoon felison June 16, 2018 at 5:57 pm
felis infected cats from their practices was a rare occurrence. Survival of these cases cannot clearly be attributed to the anti-protozoal therapy, but atovaquone and azithromycin combination therapy ...
via Bing News